Superior Morbidity Profile for Robotic Partial Nephrectomy

Share this content:
Superior Morbidity Profile for Robotic Partial Nephrectomy
Superior Morbidity Profile for Robotic Partial Nephrectomy

THURSDAY, Oct. 20, 2016 (HealthDay News) -- Compared with laparoscopic partial nephrectomy, robotic partial nephrectomy is associated with a superior morbidity profile, according to a meta-analysis published in the November issue of The Journal of Urology.

Jeffrey J. Leow, M.B.B.S., M.P.H., from Tan Tock Seng Hospital in Singapore, and colleagues conducted a literature review to compare outcomes of robotic versus laparoscopic partial nephrectomy. Data were included for 4,919 patients from 25 studies (2,681 underwent robotic partial nephrectomy and 2,238 underwent laparoscopic partial nephrectomy).

The researchers found that patients treated with robotic partial nephrectomy had larger tumors and higher mean R.E.N.A.L. nephrometry scores. Compared with patients treated with laparoscopic partial nephrectomy, those treated with robotic partial nephrectomy had decreased likelihood of conversion to laparoscopic/open surgery (risk ratio [RR], 0.36), any and major complications (RR, 0.84 and 0.71, respectively), positive margins (RR, 0.53), and a 4.3 minute shorter warm ischemia time. Operative times, estimated blood loss, and postoperative change in estimated glomerular filtration rate were similar for both approaches.

"This updated meta-analysis of retrospective cohort studies demonstrated that robotic partial nephrectomy confers a superior morbidity profile compared to laparoscopic partial nephrectomy in most of the examined perioperative outcomes," the authors write.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »